Athira Pharma (ATHA) Competitors $0.53 -0.01 (-2.20%) (As of 02:56 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ATHA vs. IKNA, RANI, GNLX, IMAB, SKYE, INCR, KPTI, QNCX, CNTX, and PMVPShould you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include Ikena Oncology (IKNA), Rani Therapeutics (RANI), Genelux (GNLX), I-Mab (IMAB), Skye Bioscience (SKYE), InterCure (INCR), Karyopharm Therapeutics (KPTI), Quince Therapeutics (QNCX), Context Therapeutics (CNTX), and PMV Pharmaceuticals (PMVP). These companies are all part of the "pharmaceutical products" industry. Athira Pharma vs. Ikena Oncology Rani Therapeutics Genelux I-Mab Skye Bioscience InterCure Karyopharm Therapeutics Quince Therapeutics Context Therapeutics PMV Pharmaceuticals Athira Pharma (NASDAQ:ATHA) and Ikena Oncology (NASDAQ:IKNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking and institutional ownership. Do institutionals & insiders have more ownership in ATHA or IKNA? 57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 75.0% of Ikena Oncology shares are held by institutional investors. 19.8% of Athira Pharma shares are held by company insiders. Comparatively, 5.9% of Ikena Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is ATHA or IKNA more profitable? Ikena Oncology's return on equity of -36.88% beat Athira Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Athira PharmaN/A -115.62% -88.94% Ikena Oncology N/A -36.88%-33.08% Do analysts rate ATHA or IKNA? Athira Pharma currently has a consensus price target of $13.83, indicating a potential upside of 2,510.06%. Ikena Oncology has a consensus price target of $3.00, indicating a potential upside of 91.69%. Given Athira Pharma's higher possible upside, research analysts clearly believe Athira Pharma is more favorable than Ikena Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Ikena Oncology 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk & volatility, ATHA or IKNA? Athira Pharma has a beta of 2.99, meaning that its share price is 199% more volatile than the S&P 500. Comparatively, Ikena Oncology has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Does the MarketBeat Community prefer ATHA or IKNA? Ikena Oncology received 10 more outperform votes than Athira Pharma when rated by MarketBeat users. Likewise, 58.82% of users gave Ikena Oncology an outperform vote while only 54.05% of users gave Athira Pharma an outperform vote. CompanyUnderperformOutperformAthira PharmaOutperform Votes2054.05% Underperform Votes1745.95% Ikena OncologyOutperform Votes3058.82% Underperform Votes2141.18% Which has preferable earnings & valuation, ATHA or IKNA? Ikena Oncology has higher revenue and earnings than Athira Pharma. Ikena Oncology is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAthira PharmaN/AN/A-$117.67M-$2.85-0.19Ikena Oncology$659K114.60-$68.17M-$1.23-1.27 Does the media favor ATHA or IKNA? In the previous week, Ikena Oncology had 9 more articles in the media than Athira Pharma. MarketBeat recorded 11 mentions for Ikena Oncology and 2 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 1.89 beat Ikena Oncology's score of 0.29 indicating that Athira Pharma is being referred to more favorably in the media. Company Overall Sentiment Athira Pharma Very Positive Ikena Oncology Neutral SummaryIkena Oncology beats Athira Pharma on 11 of the 16 factors compared between the two stocks. Ad DarwinHow Low-Cost Stocks Generate Monthly IncomeAre you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!👉 Yes, I Want the Free Report! 👈 Get Athira Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHA vs. The Competition Export to ExcelMetricAthira PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.50M$2.96B$5.23B$9.26BDividend YieldN/A1.91%5.12%4.28%P/E Ratio-0.1946.4987.8717.28Price / SalesN/A422.161,162.56123.53Price / CashN/A174.7643.3837.82Price / Book0.154.004.864.99Net Income-$117.67M-$42.00M$120.72M$225.21M7 Day Performance-3.28%4.16%2.88%4.63%1 Month Performance-14.52%-0.22%17.99%2.54%1 Year Performance-76.34%16.79%29.13%17.21% Athira Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHAAthira Pharma3.4471 of 5 stars$0.53-2.2%$13.83+2,509.6%-74.9%$20.50MN/A-0.1940Short Interest ↓Positive NewsIKNAIkena Oncology3.2713 of 5 stars$1.66+7.1%$3.00+80.7%-32.3%$80.11M$659,000.00-1.3570Analyst ForecastShort Interest ↓News CoverageGap UpHigh Trading VolumeRANIRani Therapeutics3.1176 of 5 stars$1.40-0.4%$11.71+739.7%-58.1%$79.92M$2.72M-1.32110GNLXGenelux0.9396 of 5 stars$2.29+0.9%$18.25+696.9%-83.0%$79.09M$8,000.00-2.4110Gap DownIMABI-Mab2.1718 of 5 stars$0.97+5.1%$8.00+724.7%-41.9%$79.06M$3.27M0.0034Short Interest ↑SKYESkye Bioscience1.1388 of 5 stars$2.60-3.7%$18.67+617.9%-13.9%$78.88MN/A0.0011News CoverageGap DownINCRInterCure0.8576 of 5 stars$1.72+15.4%N/A+26.9%$78.39M$272.67M0.00350Short Interest ↓Gap UpHigh Trading VolumeKPTIKaryopharm Therapeutics3.7313 of 5 stars$0.62-2.4%$5.00+706.7%-27.8%$78.21M$148.44M-0.54380Gap UpQNCXQuince Therapeutics2.8597 of 5 stars$1.75-1.7%$8.67+395.2%+51.3%$77.00MN/A-1.4160CNTXContext Therapeutics2.4677 of 5 stars$1.02-0.2%$6.80+568.1%+4.5%$76.33MN/A-1.127Short Interest ↑News CoveragePositive NewsGap UpHigh Trading VolumePMVPPMV Pharmaceuticals1.9034 of 5 stars$1.46-2.7%$5.80+297.3%-50.8%$75.55MN/A-1.4650Short Interest ↑ Related Companies and Tools Related Companies IKNA Competitors RANI Competitors GNLX Competitors IMAB Competitors SKYE Competitors INCR Competitors KPTI Competitors QNCX Competitors CNTX Competitors PMVP Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATHA) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partnersliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athira Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
